Talking Tumors: Filling Data Gaps in Multiple Myeloma

We recently traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma. Although the treatment paradigm in multiple myeloma is guided by transplant eligibility, and grounded in the use of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, certain elements of practice are not as well described.

Therefore, we sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.